Mesoblast logo

MSB - Mesoblast News Story

A$1.74 -0.0  -2.5%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £572.2m
Enterprise Value £588.4m
Revenue £11.8m
Position in Universe 294th / 1907

Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board

Mon 29th March, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210329:nGNXdv7tw&default-theme=true


NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;
ASX:MSB), global leader in allogeneic cellular medicines for inflammatory
diseases, today announced that Philip J. Facchina has joined its Board of
Directors. Mr Facchina is Chief Strategy Officer of SurgCenter Development
(SurgCenter), one of the largest private operators of ambulatory surgical
centers (ASC) in the US specializing in spine, orthopaedic and total joint
procedures. The principals of SurgCenter were the lead investors in
Mesoblast’s successful US$110 million private placement, completed earlier
this month.

Mr Facchina brings more than 35 years of experience in corporate strategy,
finance, and business development across several industries, including
healthcare. Since 2018, Mr Facchina has been Chief Strategy Officer at
SurgCenter, overseeing the company’s strategic relationships, including its
relationships with the broad US ASC market and its constituents. Over its
three-decade history, SurgCenter has developed approximately 225 ambulatory
centers, and partnered with thousands of leading physicians throughout the US.
Prior to SurgCenter, Mr Facchina spent two decades in the public and private
capital markets, where he directly managed public and private capital
transactions of equity and debt, led M&A and special advisory processes
including take-privates. From 2008 to 2017, Mr Facchina served as a Partner,
Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset
Management, an institutional investment management firm, and from 1998 to 2008
Mr Facchina led the technology, media, and communications and healthcare
investment banking groups of FBR Capital Markets. Mr Facchina currently serves
as an independent director for ViON Corporation and MilltechFX, and is Advisor
to the CEO of Johanna Foods Inc. Previously, among other directorships and
committee posts, Mr. Facchina served on the Board of Web.com (Nasdaq:WEB),
where he led Corporate Governance.

Commenting on his appointment Mr Facchina said, “My fellow principals at
SurgCenter and I are very excited about the future potential for Mesoblast
across the breadth of its platform technology from chronic heart failure and
inflammatory bowel disease to the potential treatment for chronic low back
pain. I welcome the opportunity to make a significant contribution to the
success in bringing these potential treatments to market and look forward to
working with the Board and management team.”

Mesoblast Chief Executive Dr Silviu Itescu stated, “We are pleased to have
Phil join our board. He brings expertise in financial and strategic operations
together with healthcare knowledge that will be invaluable to Mesoblast as we
continue to grow.”

About Mesoblast 
 Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular
medicines for the treatment of severe and life-threatening inflammatory
conditions. The Company has leveraged its proprietary mesenchymal lineage cell
therapy technology platform to establish a broad portfolio of late-stage
product candidates which respond to severe inflammation by releasing
anti-inflammatory factors that counter and modulate multiple effector arms of
the immune system, resulting in significant reduction of the damaging
inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio
with protection extending through to at least 2040 in all major markets. The
Company’s proprietary manufacturing processes yield industrial-scale,
cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with
defined pharmaceutical release criteria, are planned to be readily available
to patients worldwide.

Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced
chronic heart failure and chronic low back pain. Remestemcel-L is being
developed for inflammatory diseases in children and adults including steroid
refractory acute graft versus host disease and moderate to severe acute
respiratory distress syndrome. Two products have been commercialized in Japan
and Europe by Mesoblast’s licensees, and the Company has established
commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is
listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).
For more information, please see www.mesoblast.com, LinkedIn: Mesoblast
Limited and Twitter: @Mesoblast

Forward-Looking Statements 
 This announcement includes forward-looking statements that relate to future
events or our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to differ materially from any
future results, levels of activity, performance or achievements expressed or
implied by these forward-looking statements. We make such forward-looking
statements pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Forward-looking statements should not be read as a guarantee of future
performance or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the differences may be
material and adverse. Forward-looking statements include, but are not limited
to, statements about the initiation, timing, progress and results of
Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and
development programs; Mesoblast’s ability to advance product candidates
into, enroll and successfully complete, clinical studies, including
multi-national clinical trials; Mesoblast’s ability to advance its
manufacturing capabilities; the timing or likelihood of regulatory filings and
approvals, manufacturing activities and product marketing activities, if any;
the commercialization of Mesoblast’s product candidates, if approved;
regulatory or public perceptions and market acceptance surrounding the use of
stem-cell based therapies; the potential for Mesoblast’s product candidates,
if any are approved, to be withdrawn from the market due to patient adverse
events or deaths; the potential benefits of strategic collaboration agreements
and Mesoblast’s ability to enter into and maintain established strategic
collaborations; Mesoblast’s ability to establish and maintain intellectual
property on its product candidates and Mesoblast’s ability to successfully
defend these in cases of alleged infringement; the scope of protection
Mesoblast is able to establish and maintain for intellectual property rights
covering its product candidates and technology; estimates of Mesoblast’s
expenses, future revenues, capital requirements and its needs for additional
financing; Mesoblast’s financial performance; developments relating to
Mesoblast’s competitors and industry; and the pricing and reimbursement of
Mesoblast’s product candidates, if approved. You should read this press
release together with our risk factors, in our most recently filed reports
with the SEC or on our website. Uncertainties and risks that may cause
Mesoblast’s actual results, performance or achievements to be materially
different from those which may be expressed or implied by such statements, and
accordingly, you should not place undue reliance on these forward-looking
statements. We do not undertake any obligations to publicly update or revise
any forward-looking statements, whether as a result of new information, future
developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

 Corporate Communications / Investors  Media                        
 Paul Hughes                           Kristen Bothwell             
 T: +61 3 9639 6036                    T: +1 917 613 5434           
 E: investors@mesoblast.com            E: kbothwell@rubenstein.com  

(https://www.globenewswire.com/NewsRoom/AttachmentNg/1c99bb36-c17b-469c-b838-bc7244df06f2)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.